Takeda Pharmaceutical Company Limited NYSE:TAK

Takeda Pharmaceutical Company Limited stock price today

$15.2
+1.92
+14.54%
Financial Health
0
1
2
3
4
5
6
7
8
9

Takeda Pharmaceutical Company Limited stock price monthly change

-1.26%
month

Takeda Pharmaceutical Company Limited stock price quarterly change

-1.26%
quarter

Takeda Pharmaceutical Company Limited stock price yearly change

-5.69%
year

Takeda Pharmaceutical Company Limited key metrics

Market Cap
41.45B
Enterprise value
10.82T
P/E
11.42
EV/Sales
2.38
EV/EBITDA
8.70
Price/Sales
1.46
Price/Book
0.47
PEG ratio
N/A
EPS
47.69
Revenue
3.78T
EBITDA
984.56B
Income
74.51B
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
6.38%
Oper. margin
11.21%
Gross margin
55.23%
EBIT margin
11.21%
EBITDA margin
26.04%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Takeda Pharmaceutical Company Limited stock price history

Takeda Pharmaceutical Company Limited stock forecast

Takeda Pharmaceutical Company Limited financial statements

Takeda Pharmaceutical Company Limited (NYSE:TAK): Profit margin
Dec 2021 901.29B 57.77B 6.41%
Mar 2022 873.28B -11.37B -1.3%
Mar 2023 956.15B 31.13B 3.26%
Mar 2024 1.05T -3.01B -0.29%
Takeda Pharmaceutical Company Limited (NYSE:TAK): Analyst Estimates
Sep 2025 1.00T 0
Oct 2025 1.00T 0
Dec 2025 1.05T 0
Mar 2026 1.03T 0
  • Analysts Price target

  • Financials & Ratios estimates

Takeda Pharmaceutical Company Limited (NYSE:TAK): Earnings per share (EPS)
2022-10-27 0.52 0.52
3.84%
Yield TTM
Takeda Pharmaceutical Company Limited (NYSE:TAK): Payout ratio
Payout ratio 101.62%
Takeda Pharmaceutical Company Limited (NYSE:TAK): Dividend Yield
2020 11.12%
2021 8.98%
2022 10.41%
2023 8.23%
2024 8.77%
Takeda Pharmaceutical Company Limited (NYSE:TAK): Debt to assets
Sep 2022 14588847000000 7.87T 53.98%
Dec 2022 13504705000000 7.32T 54.26%
Mar 2023 13957750000000 7.60T 54.47%
Mar 2024 15108792000000 7.83T 51.86%
Takeda Pharmaceutical Company Limited (NYSE:TAK): Cash Flow
Dec 2021 347.51B -69.13B -168.06B
Mar 2022 375.58B -25.63B -243.8B
Mar 2023 293.69B -438.49B -6.6B
Mar 2024 272.47B -77.06B -36.53B

Takeda Pharmaceutical Company Limited alternative data

Takeda Pharmaceutical Company Limited (NYSE:TAK): Employee count
Sep 2023 49,095
Oct 2023 49,095
Nov 2023 49,095
Dec 2023 49,095
Jan 2024 49,095
Feb 2024 49,095
Mar 2024 49,095
Apr 2024 49,095
May 2024 49,095
Jun 2024 49,095
Jul 2024 49,281

Takeda Pharmaceutical Company Limited other data

3.22% -1.08%
of TAK is owned by hedge funds
50.77M -17.09M
shares is hold by hedge funds
Patent
Grant
Filling date: 4 Oct 2018 Issue date: 20 Sep 2022
Grant
Filling date: 6 Mar 2020 Issue date: 13 Sep 2022
Grant
Filling date: 17 Oct 2019 Issue date: 6 Sep 2022
Grant
Filling date: 17 Mar 2014 Issue date: 6 Sep 2022
Application
Filling date: 13 May 2022 Issue date: 1 Sep 2022
Application
Filling date: 13 May 2022 Issue date: 1 Sep 2022
Application
Filling date: 7 Mar 2022 Issue date: 1 Sep 2022
Application
Filling date: 28 Jul 2020 Issue date: 1 Sep 2022
Application
Filling date: 7 Jul 2020 Issue date: 1 Sep 2022
Grant
Filling date: 26 Mar 2018 Issue date: 30 Aug 2022
Insider Compensation
Mr. Christophe Weber (1966) Pres, Chief Executive Officer & Representative Director $12,980,000
Dr. Andrew S. Plump (1965) Pres of R&D and Representative Director
$6,680,000
Mr. Constantine Saroukos (1971) Chief Financial Officer & Representative Director
$4,690,000
Mr. Yasuhiko Yamanaka (1956) Advisor
$329,990
Friday, 27 December 2024
businesswire.com
Saturday, 7 December 2024
seekingalpha.com
Tuesday, 3 December 2024
benzinga.com
businesswire.com
Wednesday, 20 November 2024
businesswire.com
Friday, 15 November 2024
youtube.com
Thursday, 31 October 2024
seekingalpha.com
reuters.com
businesswire.com
Monday, 7 October 2024
seekingalpha.com
Thursday, 3 October 2024
zacks.com
zacks.com
Thursday, 26 September 2024
businesswire.com
Tuesday, 24 September 2024
businesswire.com
Wednesday, 18 September 2024
businesswire.com
Tuesday, 17 September 2024
zacks.com
zacks.com
Wednesday, 4 September 2024
reuters.com
Monday, 12 August 2024
benzinga.com
Wednesday, 7 August 2024
benzinga.com
Friday, 2 August 2024
seekingalpha.com
Thursday, 1 August 2024
businesswire.com
Wednesday, 31 July 2024
businesswire.com
Monday, 29 July 2024
investorplace.com
Friday, 26 July 2024
seekingalpha.com
Friday, 19 July 2024
seekingalpha.com
Thursday, 27 June 2024
seekingalpha.com
Wednesday, 26 June 2024
businesswire.com
Tuesday, 25 June 2024
youtube.com
Monday, 24 June 2024
businesswire.com
  • What's the price of Takeda Pharmaceutical Company Limited stock today?

    One share of Takeda Pharmaceutical Company Limited stock can currently be purchased for approximately $15.2.

  • When is Takeda Pharmaceutical Company Limited's next earnings date?

    Unfortunately, Takeda Pharmaceutical Company Limited's (TAK) next earnings date is currently unknown.

  • Does Takeda Pharmaceutical Company Limited pay dividends?

    Yes, Takeda Pharmaceutical Company Limited pays dividends and its trailing 12-month yield is 3.84% with 102% payout ratio.It means that the company is paying a dividend greater than earnings. The last Takeda Pharmaceutical Company Limited stock dividend of $0.4 was paid on 6 Sep 2025.

  • How much money does Takeda Pharmaceutical Company Limited make?

    Takeda Pharmaceutical Company Limited has a market capitalization of 41.45B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 19.47% to 4.26T US dollars. Takeda Pharmaceutical Company Limited earned 144.07B US dollars in net income (profit) last year or $0.52 on an earnings per share basis.

  • What is Takeda Pharmaceutical Company Limited's stock symbol?

    Takeda Pharmaceutical Company Limited is traded on the NYSE under the ticker symbol "TAK".

  • What is Takeda Pharmaceutical Company Limited's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Takeda Pharmaceutical Company Limited?

    Shares of Takeda Pharmaceutical Company Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Takeda Pharmaceutical Company Limited's key executives?

    Takeda Pharmaceutical Company Limited's management team includes the following people:

    • Mr. Christophe Weber Pres, Chief Executive Officer & Representative Director(age: 59, pay: $12,980,000)
    • Dr. Andrew S. Plump Pres of R&D and Representative Director(age: 60, pay: $6,680,000)
    • Mr. Constantine Saroukos Chief Financial Officer & Representative Director(age: 54, pay: $4,690,000)
    • Mr. Yasuhiko Yamanaka Advisor(age: 69, pay: $329,990)
  • How many employees does Takeda Pharmaceutical Company Limited have?

    As Jul 2024, Takeda Pharmaceutical Company Limited employs 49,281 workers, which is 0% more then previous month and 0% more then previous quarter.

  • When Takeda Pharmaceutical Company Limited went public?

    Takeda Pharmaceutical Company Limited is publicly traded company for more then 15 years since IPO on 5 Jan 2010.

  • What is Takeda Pharmaceutical Company Limited's official website?

    The official website for Takeda Pharmaceutical Company Limited is takeda.com.

  • How can i contact Takeda Pharmaceutical Company Limited?

    Takeda Pharmaceutical Company Limited can be reached via phone at +81 3 3278 2111.

Takeda Pharmaceutical Company Limited company profile:

Takeda Pharmaceutical Company Limited

takeda.com
Exchange:

NYSE

Full time employees:

49,281

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

1-1, Nihonbashi-Honcho 2-chome
Tokyo, 103-8668

CIK: 0001395064
ISIN: US8740602052
CUSIP: 874060205